Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 4, 2007

View Archived Issues

Multiple studies of SCH-527123 in healthy subjects reported

Phase III, other data on bazedoxifene presented

Snapshots of recent in vitro and pharmacokinetic studies of ceftaroline

NeuroSearch seeks approval in Europe to commence phase III trials with ACR-16

(R)-(+) isomer of zileuton enters clinical trials

Not approvable letter assigned for expanded indication for Frova

Trophos begins patient enrollment for TRO-19622 SMA trial

DiaMedica reports promising phase II results with DM-71 for type 2 diabetes

Primary endpoint not reached in phase IIb trial of ANX-510

One-year treatment with tesamorelin shows promise in phase III trial

FDA approves SymlinPen device and issues not approvable letter for expanded Symlin indication

Kyorin launches bronchial asthma treatment for young children

Preclinical antidiabetic activity of Chinese herbal medicinal compound DC-250188

Preclinical profile of CBR-2092, a novel rifamycin-quinolone hybrid antibiotic

Topical nerve growth factor relieves dry eye symptoms in vivo

Recent AstraZeneca patents describe new antiasthmatic agents

Novel coagulation factor VIIa inhibitors emerge from Bristol-Myers Squibb R&D

GlaxoSmithKline discovers novel antianemic agents

Phase II studies show activity of SNS-595 in lung cancer

Axcan licenses rights to Cx-401 for perianal fistulas

FASgen achieves significant milestone in cancer drug program

Isis grants rights to two diabetes drugs to Ortho-McNeil

Newron initiates phase II studies for ralfinamide in post-surgical pain

OSI and Aveo collaborate on oncology drug discovery program

Daiichi Sankyo seeks approval of combination hypertension candidate in Europe

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 2, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 31, 2026
Hematopoietic stem cell research points to leukemia’s early roots
BioWorld Science
Hematopoietic stem cell (HSC) research over the past century has shown that leukemia may be driven by an invisible hand of inflammation. The bone marrow and...
Hengrui discovers new Nav1.8 blockers
BioWorld Science
Researchers from Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have patented new sodium channel protein type 10 subunit α...
Molecular signatures show subtypes in neurodegenerative diseases
BioWorld Science
Parkinson’s disease is a progressive neurodegenerative disorder best known for its motor symptoms. However, a proportion of patients also develop dementia as the...